New RAF blocker tested for tough tumors, but study halted early
Disease control
Terminated
This early-phase study tested a new oral drug, BGB-3245, designed to block a protein called RAF that helps some tumors grow. It involved 109 adults with advanced solid tumors that had a specific BRAF mutation and had stopped responding to other treatments. The main goals were to …
Phase: PHASE1 • Sponsor: MapKure, LLC • Aim: Disease control
Last updated May 11, 2026 02:28 UTC